24
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Complement activation has been implicated in the pathogenesis of severe SARS-CoV-2 infection. However, it remains to be determined whether increased complement activation is a broad indicator of critical illness (and thus, no different in COVID-19). It is also unclear which pathways are contributing to complement activation in COVID-19, and if complement activation is associated with certain features of severe SARS-CoV-2 infection, such as endothelial injury and hypercoagulability. To address these questions, we investigated complement activation in the plasma from patients with COVID-19 prospectively enrolled at two tertiary care centers: Washington University School of Medicine (n=134) and Yale School of Medicine (n=49). We compared our patients to two non-COVID cohorts: (a) patients hospitalized with influenza (n=54), and (b) patients admitted to the intensive care unit (ICU) with acute respiratory failure requiring invasive mechanical ventilation (IMV, n=22). We demonstrate that circulating markers of complement activation are elevated in patients with COVID-19 compared to those with influenza and to patients with non-COVID-19 respiratory failure. Further, the results facilitate distinguishing those who are at higher risk of worse outcomes such as requiring ICU admission, or IMV. Moreover, the results indicate enhanced activation of the alternative complement pathway is most prevalent in patients with severe COVID-19 and is associated with markers of endothelial injury (i.e., angiopoietin-2) as well as hypercoagulability (i.e., thrombomodulin and von Willebrand factor). Our findings identify complement activation to be a distinctive feature of COVID-19, and provide specific targets that may be utilized for risk prognostication, drug discovery and personalized clinical trials.

          Abstract

          Increased complement activation is observed in COVID-19 compared to non-COVID respiratory illness, and is a key marker of organ failure.

          Related collections

          Most cited references61

          • Record: found
          • Abstract: found
          • Article: not found

          Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

          Progressive respiratory failure is the primary cause of death in the coronavirus disease 2019 (Covid-19) pandemic. Despite widespread interest in the pathophysiology of the disease, relatively little is known about the associated morphologic and molecular changes in the peripheral lung of patients who die from Covid-19.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review

            The coronavirus disease 2019 (COVID-19) pandemic, due to the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused a worldwide sudden and substantial increase in hospitalizations for pneumonia with multiorgan disease. This review discusses current evidence regarding the pathophysiology, transmission, diagnosis, and management of COVID-19.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

              Summary Viral pandemics, such as the one caused by SARS-CoV-2, pose an imminent threat to humanity. Because of its recent emergence, there is a paucity of information regarding viral behavior and host response following SARS-CoV-2 infection. Here we offer an in-depth analysis of the transcriptional response to SARS-CoV-2 compared with other respiratory viruses. Cell and animal models of SARS-CoV-2 infection, in addition to transcriptional and serum profiling of COVID-19 patients, consistently revealed a unique and inappropriate inflammatory response. This response is defined by low levels of type I and III interferons juxtaposed to elevated chemokines and high expression of IL-6. We propose that reduced innate antiviral defenses coupled with exuberant inflammatory cytokine production are the defining and driving features of COVID-19.
                Bookmark

                Author and article information

                Journal
                Sci Immunol
                Sci Immunol
                sciimmunol
                immunology
                Science Immunology
                American Association for the Advancement of Science
                2470-9468
                13 May 2021
                13 May 2021
                : 6
                : 59
                : eabh2259
                Affiliations
                [1 ]Division of Pulmonary and Critical Care Medicine, John T. Milliken Department of Medicine, Washington University School of Medicine; St. Louis, USA.
                [2 ]Division of Hospital Medicine, John T. Milliken Department of Medicine, Washington University School of Medicine; St. Louis, USA.
                [3 ]Marian University; Indianapolis, USA.
                [4 ]University of Pittsburgh; Pittsburgh, USA.
                [5 ]Section of Hematology, Department of Internal Medicine, Yale School of Medicine; New Haven, USA.
                [6 ]Yale School of Medicine; New Haven, USA.
                [7 ]Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine; New Haven, USA.
                [8 ]Section of Immunology, Department of Internal Medicine, Yale School of Medicine; New Haven, USA.
                [9 ]Yale New Haven Health System; New Haven, USA.
                [10 ]Department of Pathology and Immunology, Washington University School of Medicine; St. Louis, USA.
                [11 ]Department of Emergency Medicine, Washington University School of Medicine; St. Louis, USA.
                [12 ]Division of Rheumatology, John T. Milliken Department of Medicine, Washington University School of Medicine; St. Louis, USA.
                [13 ]Division of Infectious Diseases, John T. Milliken Department of Medicine, Washington University School of Medicine; St. Louis, USA.
                [14 ]Division of Biostatistics, Washington University School of Medicine; St. Louis, USA.
                [15 ]Section of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, Yale School of Medicine; New Haven, USA.
                Author notes
                [* ]Corresponding author. Email: hkulkarn@ 123456wustl.edu
                Author information
                https://orcid.org/0000-0002-0970-0893
                https://orcid.org/0000-0002-4638-5095
                https://orcid.org/0000-0002-2368-9256
                https://orcid.org/0000-0002-3726-0071
                https://orcid.org/0000-0002-9463-3022
                https://orcid.org/0000-0002-4306-5061
                https://orcid.org/0000-0002-1624-4427
                https://orcid.org/0000-0002-5992-5433
                https://orcid.org/0000-0002-6133-4771
                https://orcid.org/0000-0002-7430-0626
                https://orcid.org/0000-0001-9555-2550
                https://orcid.org/0000-0003-2682-7316
                https://orcid.org/0000-0001-8265-9471
                https://orcid.org/0000-0002-5469-0727
                https://orcid.org/0000-0003-4074-0516
                https://orcid.org/0000-0002-0711-6343
                https://orcid.org/0000-0002-5968-3948
                https://orcid.org/0000-0002-3860-5473
                https://orcid.org/0000-0003-3508-2678
                https://orcid.org/0000-0003-4830-5084
                Article
                abh2259
                10.1126/sciimmunol.abh2259
                8158979
                34446527
                84cebfab-4d97-4713-8f47-913ac04a519e
                Copyright © 2021, American Association for the Advancement of Science

                This is an open-access article distributed under the terms of the Creative Commons Attribution license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 24 February 2021
                : 11 May 2021
                Funding
                Funded by: doi http://dx.doi.org/10.13039/100000050, National Heart, Lung, and Blood Institute;
                Funded by: doi http://dx.doi.org/10.13039/100000053, National Eye Institute;
                Funded by: doi http://dx.doi.org/10.13039/100000057, National Institute of General Medical Sciences;
                Funded by: doi http://dx.doi.org/10.13039/100000060, National Institute of Allergy and Infectious Diseases;
                Funded by: doi http://dx.doi.org/10.13039/100000069, National Institute of Arthritis and Musculoskeletal and Skin Diseases;
                Funded by: doi http://dx.doi.org/10.13039/100000938, Robert E. Leet and Clara Guthrie Patterson Trust;
                Funded by: doi http://dx.doi.org/10.13039/100000968, American Heart Association;
                Funded by: doi http://dx.doi.org/10.13039/100002076, Emergency Medicine Foundation;
                Funded by: doi http://dx.doi.org/10.13039/100007338, Foundation for Barnes-Jewish Hospital;
                Funded by: doi http://dx.doi.org/10.13039/100007930, Institute of Clinical and Translational Sciences;
                Funded by: doi http://dx.doi.org/10.13039/100009340, Children's Discovery Institute;
                Categories
                Research Articles
                Research Articles
                R-Articles
                Coronavirus

                Comments

                Comment on this article